Biotech & Pharma Updates | January 21 - 22, 2026
🧬 Samsung Biologics becomes first Korean biopharma to surpass 2 trillion won ($1.36B) profit threshold in 2025, Sandoz eyes $322B biosimilar opportunity as 50+ biologics lose patent protection in golden decade ahead, global pharma manufacturing output surged 9.1% in 2025 due to US tariff threat front-loading activities, Corxel Pharmaceuticals raises $287M Series D1 for obesity pill development and testing, BioMarin veterans launch Mendra with $82M Series A to use AI for rare disease drug development, Corcept Therapeutics' relacorilant shows Ph3 overall survival benefit in platinum-resistant ovarian cancer, Bristol Myers Squibb + Janux Therapeutics partner on tumor-activated cancer drugs, $50M upfront, $850M total deal value
